Dr. Kanwaljeet “Sunny” Anand is the preeminent expert on opioid addiction in newborns and the former chief of pediatrics at Stanford University. Dr. Anand was a Rhodes scholar at University of Oxford. He did a post-doctoral fellowship in Anesthesia at Harvard, Pediatrics residency training at Boston’s Children’s Hospital, and Critical Care Medicine fellowship training at Massachusetts General Hospital in Boston. Dr. Anand is on the executive committee at the Pediatric Pain Research Network, and has published over 260 peer reviewed articles and 47 book chapters. Dr. Anand has no ties to the pharmaceutical industry defendants, and has not accepted research funding or speaking fees from them.
Brent Bell PA-C, Ph.D has practiced medicine for 26 years in the World’s Largest Medical Center in Houston, Texas. The majority of his tenure was spent at both MD Anderson Cancer Center and Houston Methodist. He graduated in 1993 as a Physician Assistant and entered practice at the beginning of the opioid crisis.
His entire career was in Oncology, where opioids played a very necessary role. Brent has published extensively and has many credits and accolades regarding his clinical research. He is highly regarded by both patients as their advocate and by physicians, many of them chairmen of their departments, for running their world-class services. Brent was one of two initial team leaders who implemented the MD Anderson Physician Assistant Residency Program in Oncology which still functions because of his efforts to this day.
John Konsin, Co-founder and CEO, Prapela, LLC, is an expert with 37 years in affordable medical devices and consumer products for infants and caregivers, specializing in devices that help infants relax, breathe and sleep. These devices have helped infants struggling with colic to heart disease. Mr. Konsin is currently conducting a study with Harvard University involving 230 babies exposed to opioids in the womb and a control group of non-exposed babies to assess products which reduce respiration, heart rate and sleep apnea; the study will conclude in 2021.